# Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a

> **NCT03320265** · PHASE2 · TERMINATED · sponsor: **Athera Biotechnologies AB** · enrollment: 10 (actual)

## Conditions studied

- Arterial Inflammation
- Cardiovascular Diseases

## Interventions

- **DRUG:** PC-mAb
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03320265
- **Lead sponsor:** Athera Biotechnologies AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-11
- **Primary completion:** 2018-03-19
- **Final completion:** 2018-07-03
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Terminated
- **Last updated:** 2018-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03320265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03320265, "Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03320265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*